Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
AssigneeJanssen Pharmaceutica NV
InventorMaud Urbanski
Life of this patent
Estimating the term…
Abstract
This invention relates to to substituted benzimidazole-O glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.
Claims35
1-20. (canceled)
A method for treating diabetes in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a pharmaceutical composition of claim 19.
A method for lowering serum glucose in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a pharmaceutical composition of claim 19.
A method for treating impaired glucose tolerance in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a pharmaceutical composition of claim 19.
A method for treating or inhibiting impaired glucose tolerance in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a pharmaceutical composition of claim 19.
A method for reducing the body mass index, body weight, or percentage body fat in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a pharmaceutical composition of claim 19.
A method for inhibiting the sodium glucose transporter in a cell, by exposing said cell to a compound of claim 1 or a metabolite thereof.
A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a subject, comprising
- (a) administering to said subject a jointly effective amount of a glucose reabsorption inhibitor of formula (III);
- and
- (b) administering to said subject a jointly effective amount of a second antidiabetic agent,
- said co-administration being in any order and the combined jointly effective amounts providing the desired therapeutic effect.
A method for inhibiting the onset of diabetes or Syndrome X, or associated symptoms or complications thereof in a subject, said method comprising
- (a) administering to said subject a jointly effective amount of a glucose reabsorption inhibitor of formula (III);
- and
- (b) administering to said subject a jointly effective amount of a second antidiabetic agent,
- said co-administration being in any order and the combined jointly effective amounts providing the desired prophylactic effect.
A pharmaceutical composition comprising a glucose reabsorption inhibitor of formula (III), a second antidiabetic agent, and a pharmaceutically acceptable carrier.
A process for formulating a pharmaceutical composition, comprising formulating together a glucose reabsorption inhibitor, a second antidiabetic agent, and a pharmaceutically acceptable carrier.
A process for making a pharmaceutical composition comprising mixing one or more glucose reabsorption inhibitors in combination with a second antidiabetic agent for the preparation of a medicament for treating a condition selected from IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.
A method for inhibiting the progression of a prediabetic condition in a subject to a diabetic condition, comprising
- (a) administering to said subject a jointly effective amount of a glucose reabsorption inhibitor of formula (III);
- and
- (b) administering to said subject a jointly effective amount of an second diabetic agent,
- said co-administration being in any order and the combined jointly effective amounts providing the desired inhibiting effect.
Dependencies are inferred from the claim text.